Apadenoson, formerly known as ATL-146e; BMS-068645; DWH-146e, is an adenosine A2A agonist potentially for the treatment of coronary artery disease. ATL-146e attenuates experimental posthemorrhagic vasospasm. ATL-146e prevents concanavalin A-induced acute liver injury in mice. ATL-146e reduces systemic tumor necrosing factor-alpha and spinal cord capillary platelet-endothelial cell adhesion molecule-1 expression after spinal cord ischemia. ATL-146e, reduces paralysis and apoptosis during rabbit spinal cord reperfusion. References: Patel RA, Glover DK, Broisat A, Kabul HK, Ruiz M, Goodman NC, Kramer CM, Meerdink DJ, Linden J, Beller GA. Reduction in myocardial infarct size at 48 hours after brief intravenous infusion of ATL-146e, a highly selective adenosine A2A receptor agonist. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H637-42. doi: 10.1152/ajpheart.00705.2008. Epub 2009 Jun 5. PubMed PMID: 19502555; PubMed Central PMCID: PMC2724215.

纯度：≥98%

CAS：250386-15-3